zoledronic acid has been researched along with Dermatitis Medicamentosa in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Barua, P; Gonzalez-Mosquera, LF; Kandala, H; Podrumar, A | 1 |
Cohen, PR | 1 |
Collier, M; Mahalingam, M; Succaria, F | 1 |
Chan, JJ; Tong, PL; Yu, LL | 1 |
1 review(s) available for zoledronic acid and Dermatitis Medicamentosa
Article | Year |
---|---|
Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
Topics: Arm; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Buttocks; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Drug Eruptions; Erythema; Female; Humans; Imidazoles; Intertrigo; Lung Neoplasms; Middle Aged; Mixed Tumor, Malignant; Syndrome; Zoledronic Acid | 2015 |
3 other study(ies) available for zoledronic acid and Dermatitis Medicamentosa
Article | Year |
---|---|
Zoledronic acid-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE).
Topics: Drug Eruptions; Exanthema; Humans; Pharmaceutical Preparations; Zoledronic Acid | 2021 |
Zoledronic Acid-Induced Interface Dermatitis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Eruptions; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2015 |
Drug-induced dermatomyositis after zoledronic acid.
Topics: Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Drug Eruptions; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Zoledronic Acid | 2012 |